Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Feasibility of Allogenic Mesenchymal Stromal Cells in the Treatment of COVID-19

NCT04467047 is registered in ClinicalTrials.gov with Hospital de Clinicas de Porto Alegre as lead sponsor.

NCT NCT04467047
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04467047 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Feasibility of Allogenic Mesenchymal Stromal Cells in the Treatment of COVID-19
Lead sponsor
Hospital de Clinicas de Porto Alegre
Phase
Phase 1
Overall status
Unknown status
Start date
July 25, 2020
Completion date
December 30, 2020
Enrollment
10 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov2